Economic and Clinical Benefits of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Prevention of RSV in Infants: A Cost-Effectiveness Analysis for Mexico
Year-round RSVpreF maternal vaccination would substantially reduce RSV's clinical and economic burden among infants in Mexico and likely be a cost-effective program.
Authors
- Luka Ivkovic
- Carlos A. Molina (ORCID: https://orcid.org/0000-0003-0566-9945)
- Robyn Kendall (ORCID: https://orcid.org/0000-0001-6331-5497)
- Diana Mendes (ORCID: https://orcid.org/0000-0002-1672-4906)
- Amy Law
- J Huerta (ORCID: https://orcid.org/0000-0001-7621-8864)
Institutions
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- MSD (Mexico) (MX)
Publication Details
- Journal
- Vaccines
- Published
- 2025-01-16
- DOI
- https://doi.org/10.3390/vaccines13010077
- Citations
- 1
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- Pfizer